A PYMNTS Company

US: FTC loses Impax pay-for-delay case

By  |  May 21, 2018

A patent deal in which Endo Pharmaceuticals paid generic-drug maker Impax Laboratories to forgo launching a generic version of an opioid pain medication did not violate consumer protection statutes, a Federal Trade Commission (FTC) administrative law judge ruled Friday, May 18, because the settlement’s pro-competitive benefits outweighed the anticompetitive harm, reported Law360.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The original complaint in 2012 accused Endo of working a deal in which they compensated Watson Laboratories “hundreds of millions of dollars” to hold off a generic version of Endo’s Lidoderm patch. It also accused Endo of paying Impax US$112 million in 2010 to hold off releasing an authorized generic version of Endo’s painkiller Opana. The FTC alleged Endo’s financial gain by giving it time to transition patients to a new formulation of Opana ER, “thereby maintaining its monopoly power.”

    Full Content: Law 360

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.